AHA: Fresh Produce Prescription Improves Glycemic Control
By Lori Solomon HealthDay Reporter
MONDAY, Nov. 13, 2023 -- A fresh produce prescription program can significantly improve hemoglobin A1c (HbA1c) among low-income patients with diabetes and poor glycemic control, according to a study presented at the American Heart Association Scientific Sessions 2023, held from Nov. 11 to 13 in Philadelphia.
Claudia Nau, Ph.D., from Kaiser Permanente Southern California in Pasadena, and colleagues assigned 450 eligible Kaiser Permanente Southern California patients (1:1:1) to a control group or a high- or low-dose intervention group (scaled to household size and ranging from $90 to $270 and $90 to $180, respectively). Adult participants were enrolled through Medicaid and had type 2 diabetes with at least two HbA1c values >7.5 percent in the past 12 months.
The researchers found that at baseline, HbA1c was 9.40 percent, body mass index was 34.1 kg/m2, 74 percent had elevated blood pressure or hypertension (stage 1 or 2), and 58.3 percent were food-insecure. Compared with control, HbA1c at six months was significantly lower in the intervention groups (−0.32 points). There was not a significant difference seen in reduction in HbA1c between the high- and low-dose interventions.
"The availability and affordability of fresh foods and vegetables are key social determinants of health for people managing diet-related health conditions," Nau said in a statement. "Providing healthy foods and dietary counseling can be an important complement to medical care."
One author disclosed ties to the fresh produce industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.